Michael Cloonan
CIK 1704336 · President & CEO · last filed 2026-01-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.54M
Companies
3
Total Filings
25
Lifetime Open-Market Net
-$10.70M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SION | President & CEO | 547,343 | $6.46 | $3.54M | -$6.33M | 7 | 2026-01-06 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 0 | $4.97 | $0 | $0 | 3 | 2025-06-03 |
| Sage Therapeutics, Inc. (SAGE) Delisted | Chief Business Officer | 3,190 | $8.68 | $27.7K | -$4.38M | 9 | 2021-02-12 |
Recent Filings · Page 2 of 3
25 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-21 | SION | Mixed | — | -$416.0K | EDGAR |
| 2025-08-20 | SION | Notice (144) | −25,000 | -$537.0K | EDGAR |
| 2025-06-03 | bluebird bio, Inc. (BLUE) Delisted | Disp (D) | −1,867 | $0 | EDGAR |
| 2025-02-10 | SION | Grant (A) | — | $0 | EDGAR |
| 2024-10-02 | bluebird bio, Inc. (BLUE) Delisted | Grant (A) | +37,350 | $0 | EDGAR |
| 2024-06-24 | bluebird bio, Inc. (BLUE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-12 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-05 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-30 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-14 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.